MRNA

Moderna, Inc.

Nasdaq · Biological Products, (No Diagnostic Substances) · Inc. DE · CIK 0001682852

$47.60 +0.34% $18.9B

Insider Selling Cluster (2 insiders)High Impact Filing (8/10)3 New Institutional Positions

Vol

Market Cap$18.9B

Cap SizeLarge Cap

Analyst ConsensusSell (13%)

Inst. Holders9 funds

Inst. Value$2.8B

Inst. Activity3 buys / 1 sells

Insider Activity0B / 3S

Insider Net $-$3.2M

Reddit Sentiment54° Neutral

SEC Reports9

Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001682852·Prev Close $47.44

Recent Activity

Aug 5, 2026 fda_pdufa

PDUFA: MRNA — mRNA-1010 in Seasonal flu — 2026-08-05

FDA target action date 2026-08-05 for MRNA (Moderna, Inc.). Drug: mRNA-1010. Indication: Seasonal fl

Jun 5, 2026 Insider

Mock James M sold 5,705 shares

Chief Financial Officer @ $51.59 ($294.3K)

Jun 5, 2026 Insider

Mock James M sold 11,798 shares

Chief Financial Officer @ $0.00 ($0.00)

Jun 5, 2026 Insider

Mock James M sold 11,798 shares

Chief Financial Officer @ $0.00 ($0.00)

May 31, 2026 SEC

8 firms acted on MRNA: Jefferies, Citigroup, Barclays, Argus Research, HSBC, Wolfe Research, Deutsche Bank, RBC Capital

ANALYST-UPGRADE — Impact 1/10

May 22, 2026 SEC

Two Moderna insiders sold a total of $3.02M in open-market sales over a 7-day window. Director Noubar Afeyan exercised a

CLUSTER — Impact 2/10

May 1, 2026 SEC

HSBC upgrades MRNA to Buy with $58 PT — cluster of 9 firms act; consensus deeply bearish

ANALYST-UPGRADE — Impact 1/10

Inst.

FMR LLC — DOUBLED

28,045,311 shares ($827.1M)

Price Targets

$43.30 -9.3% upside Sell

Current $47.73 Low $21.00 Median $45.00 High $69.00 20 analysts

$21.00 $69.00

Analyst Ratings

Strong Sell13% buy · 30 analysts

0Strong Buy

4Buy

19Hold

4Sell

3Strong Sell

Recent Analyst Actions

Date	Firm	Action	Rating
Jun 8, 2026	B of A Securities	MAINTAIN	Underperform → Underperform
May 4, 2026	UBS	MAINTAIN	Neutral → Neutral
May 4, 2026	Goldman Sachs	MAINTAIN	Neutral → Neutral
May 4, 2026	Evercore ISI Group	MAINTAIN	In-Line → In-Line
May 4, 2026	RBC Capital	MAINTAIN	Sector Perform → Sector Perform

Earnings Estimates

Period	EPS Est.	Range	Growth	#
Current Q	$-2.09	$-2.52 — $-1.80	2% YoY	15
Next Q	$-1.13 ▲ +1.5%	$-1.78 — $-0.33	-121% YoY	15
Current FY	$-8.65	$-9.48 — $-7.52	-19% YoY	21
Next FY	$-4.72	$-6.68 — $-0.08	45% YoY	20

Latest Reports

BULLISH ANALYST-UPGRADE 1/10

8 firms acted on MRNA: Jefferies, Citigroup, Barclays, Argus Research, HSBC, Wolfe Research, Deutsche Bank, RBC Capital

May 31, 2026

NEUTRAL ANALYST-UPGRADE 1/10

HSBC upgrades MRNA to Buy with $58 PT — cluster of 9 firms act; consensus deeply bearish

May 1, 2026

Top Institutional Holders

Fund	Value	Move
VANGUARD GROUP INC	$1.2B	—
FMR LLC	$827.1M	DOUBLED
MORGAN STANLEY	$261.6M	ADD
TWO SIGMA INVESTMENTS, LP	$217.1M	ADD
CHARLES SCHWAB INVESTMENT MANAGEMENT	$136.3M	ADD

Recent Insider Trades

Date	Insider	Type	Value
Jun 5, 2026	Mock James	F	$294.3K
Jun 5, 2026	Mock James	M	$0.00
Jun 5, 2026	Mock James	M	$0.00
Jun 5, 2026	Klinger Shannon	M	$0.00
Jun 5, 2026	Klinger Shannon	F	$294.3K

Reddit Sentiment

54°▼

Neutral

Bearish Neutral Bullish

8 mentions 4 bullish 3 bearish

9 institutional holders with $2.8B total value (95,256,056 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, MORGAN. Net buying activity: 3 institutions added/increased vs 1 reduced.

Top Institutional Holders — 2025-Q4

#	Fund	Shares	Value	% of Tracked	Last Move
1	VANGUARD GROUP INC	41,584,782	$1.2B	43.7%	—
2	FMR LLC	28,045,311	$827.1M	29.4%	DOUBLED +127.9%
3	MORGAN STANLEY	8,870,716	$261.6M	9.3%	ADD +75.1%
4	TWO SIGMA INVESTMENTS, LP	7,362,796	$217.1M	7.7%	ADD +56.2%
5	CHARLES SCHWAB INVESTMENT MANAGEMENT INC	4,621,558	$136.3M	4.9%	ADD +41.9%
6	NORGES BANK	2,702,832	$79.7M	2.8%	NEW
7	BANK OF AMERICA CORP /DE/	1,374,854	$40.5M	1.4%	TRIM -39.1%
8	RENAISSANCE TECHNOLOGIES LLC	568,400	$16.8M	0.6%	NEW
9	WELLS FARGO & COMPANY/MN	124,807	$3.7M	0.1%	NEAR_EXIT -83.8%

Recent Position Changes

Fund	Action	Prev Shares	Curr Shares	Change %	Value	Quarter
FMR LLC	DOUBLED	12,304,297	28,045,311	+127.9%	$827.1M	2025-Q4
NORGES BANK	NEW	—	2,702,832	—	$79.7M	2025-Q4
BANK OF AMERICA CORP /DE/	TRIM	2,256,571	1,374,854	-39.1%	$40.5M	2025-Q4
RENAISSANCE TECHNOLOGIES LLC	NEW	—	568,400	—	$16.8M	2025-Q4
FMR LLC	TRIM	19,645,464	12,304,297	-37.4%	$317.8M	2025-Q3
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	ADD	3,040,117	4,312,432	+41.9%	$111.4M	2025-Q3
BANK OF AMERICA CORP /DE/	ADD	1,779,309	2,256,571	+26.8%	$58.3M	2025-Q3
NORGES BANK	EXIT	3,439,999	0	-100.0%	$0.00	2025-Q3
RENAISSANCE TECHNOLOGIES LLC	EXIT	1,003,900	0	-100.0%	$0.00	2025-Q3
TWO SIGMA INVESTMENTS, LP	ADD	4,454,103	6,959,208	+56.2%	$192.0M	2025-Q2
NORGES BANK	NEW	—	3,439,999	—	$94.9M	2025-Q2
BANK OF AMERICA CORP /DE/	ADD	965,335	1,779,309	+84.3%	$49.1M	2025-Q2
RENAISSANCE TECHNOLOGIES LLC	TRIM	1,360,100	1,003,900	-26.2%	$27.7M	2025-Q2
UBS Group AG	DOUBLED	6,305,399	12,629,265	+100.3%	$358.0M	2025-Q1
CITADEL ADVISORS LLC	ADD	7,612,592	10,586,985	+39.1%	$300.1M	2025-Q1
MORGAN STANLEY	ADD	4,247,698	7,438,405	+75.1%	$210.9M	2025-Q1
TWO SIGMA INVESTMENTS, LP	DOUBLED	664,040	4,454,103	+570.8%	$126.3M	2025-Q1
RENAISSANCE TECHNOLOGIES LLC	ADD	1,010,758	1,360,100	+34.6%	$38.6M	2025-Q1
WELLS FARGO & COMPANY/MN	NEAR_EXIT	523,727	84,860	-83.8%	$2.4M	2025-Q1
NORGES BANK	EXIT	3,940,194	0	-100.0%	$0.00	2025-Q1
CITADEL ADVISORS LLC	ADD	4,920,476	7,612,592	+54.7%	$316.5M	2024-Q4
UBS Group AG	ADD	3,277,986	6,305,399	+92.4%	$262.2M	2024-Q4
RENAISSANCE TECHNOLOGIES LLC	DOUBLED	310,300	1,010,758	+225.7%	$42.0M	2024-Q4
WELLS FARGO & COMPANY/MN	ADD	333,021	523,727	+57.3%	$21.8M	2024-Q4
Mawer Investment Management Ltd.	EXIT	1,901,668	0	-100.0%	$0.00	2024-Q4

9 unique insiders with 3 transactions. Net insider value: -$3.2M ($0.00 bought, $3.2M sold).

Insider Transactions

Date	Insider	Title	Type	Shares	Price	Value
Jun 5, 2026	Mock James M	Chief Financial Officer	F	5,705	$51.59	$294.3K
Jun 5, 2026	Mock James M	Chief Financial Officer	M	11,798	$0.00	$0.00
Jun 5, 2026	Mock James M	Chief Financial Officer	M	11,798	$0.00	$0.00
Jun 5, 2026	Klinger Shannon Thyme	Chief Legal Officer	M	11,798	$0.00	$0.00
Jun 5, 2026	Klinger Shannon Thyme	Chief Legal Officer	F	5,705	$51.59	$294.3K
Jun 5, 2026	Klinger Shannon Thyme	Chief Legal Officer	M	11,798	$0.00	$0.00
Jun 4, 2026	Klinger Shannon Thyme	Chief Legal Officer	M	3,471	$30.96	$107.5K
Jun 4, 2026	Klinger Shannon Thyme	Chief Legal Officer	M	3,471	$0.00	$0.00
Jun 4, 2026	Klinger Shannon Thyme	Chief Legal Officer	SELL	3,471	$50.00	$173.6K
Jun 1, 2026	Hoge Stephen	President	M	9,282	$0.00	$0.00
Jun 1, 2026	Hoge Stephen	President	F	4,488	$47.19	$211.8K
Jun 1, 2026	Hoge Stephen	President	M	9,282	$0.00	$0.00
Jun 1, 2026	Klinger Shannon Thyme	Chief Legal Officer	F	1,047	$47.19	$49.4K
Jun 1, 2026	Klinger Shannon Thyme	Chief Legal Officer	M	2,165	$0.00	$0.00
Jun 1, 2026	Mock James M	Chief Financial Officer	M	2,475	$0.00	$0.00
Jun 1, 2026	Klinger Shannon Thyme	Chief Legal Officer	M	2,165	$0.00	$0.00
Jun 1, 2026	Mock James M	Chief Financial Officer	F	1,197	$47.19	$56.5K
Jun 1, 2026	Mock James M	Chief Financial Officer	M	2,475	$0.00	$0.00
May 28, 2026	Hoge Stephen	President	M	610	$0.00	$0.00
May 28, 2026	Hoge Stephen	President	F	295	$47.61	$14.0K
May 28, 2026	Hoge Stephen	President	M	610	$0.00	$0.00
May 28, 2026	Klinger Shannon Thyme	Chief Legal Officer	M	328	$0.00	$0.00
May 28, 2026	Mock James M	Chief Financial Officer	F	159	$47.61	$7.6K
May 28, 2026	Klinger Shannon Thyme	Chief Legal Officer	F	159	$47.61	$7.6K
May 28, 2026	Mock James M	Chief Financial Officer	M	328	$0.00	$0.00
May 28, 2026	Klinger Shannon Thyme	Chief Legal Officer	M	328	$0.00	$0.00
May 28, 2026	Mock James M	Chief Financial Officer	M	328	$0.00	$0.00
May 27, 2026	Hoge Stephen	President	F	695	$47.03	$32.7K
May 27, 2026	Hoge Stephen	President	M	1,437	$0.00	$0.00
May 27, 2026	Hoge Stephen	President	M	1,437	$0.00	$0.00
May 27, 2026	Mock James M	Chief Financial Officer	M	773	$0.00	$0.00
May 27, 2026	Klinger Shannon Thyme	Chief Legal Officer	F	374	$47.03	$17.6K
May 27, 2026	Klinger Shannon Thyme	Chief Legal Officer	M	773	$0.00	$0.00
May 27, 2026	Mock James M	Chief Financial Officer	F	374	$47.03	$17.6K
May 27, 2026	Klinger Shannon Thyme	Chief Legal Officer	M	773	$0.00	$0.00
May 27, 2026	Mock James M	Chief Financial Officer	M	773	$0.00	$0.00
May 21, 2026	AFEYAN NOUBAR	Director	M	9,263	$19.15	$177.4K
May 21, 2026	AFEYAN NOUBAR	Director	SELL	9,263	$46.84	$433.9K
May 21, 2026	AFEYAN NOUBAR	Director	M	9,263	$0.00	$0.00
May 15, 2026	Hoge Stephen	President	M	37,226	$19.15	$712.9K
May 15, 2026	Hoge Stephen	President	SELL	53,336	$48.40	$2.6M
May 15, 2026	Hoge Stephen	President	M	37,226	$0.00	$0.00
May 6, 2026	Rubenstein David M.	Director	A	2,092	$0.00	$0.00
May 6, 2026	Rubenstein David M.	Director	A	9,681	$0.00	$0.00
May 6, 2026	Hussain Abbas	Director	A	8,371	$0.00	$0.00
May 6, 2026	Horning Sandra	Director	A	2,092	$0.00	$0.00
May 6, 2026	Horning Sandra	Director	A	9,681	$0.00	$0.00
May 6, 2026	NABEL ELIZABETH G	Director	A	8,371	$0.00	$0.00
May 6, 2026	Nader Francois	Director	A	4,185	$0.00	$0.00
May 6, 2026	Nader Francois	Director	A	6,454	$0.00	$0.00

9 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 0 mixed, 6 neutral. Avg impact: 3.2/10.

BULLISH ANALYST-UPGRADE 1/10

8 firms acted on MRNA: Jefferies, Citigroup, Barclays, Argus Research, HSBC, Wolfe Research, Deutsche Bank, RBC Capital

May 31, 2026

NEUTRAL ANALYST-UPGRADE 1/10

HSBC upgrades MRNA to Buy with $58 PT — cluster of 9 firms act; consensus deeply bearish

May 1, 2026

NEUTRAL CLUSTER 2/10

Two Moderna insiders sold a total of $3.02M in open-market sales over a 7-day window. Director Nouba

May 22, 2026

NEUTRAL 144 2/10

Flagship Pioneering, LLC, a major early investor in Moderna, filed a Form 144 to sell 9,263 shares o

May 21, 2026

NEUTRAL 144 2/10

Former director Paul Sagan filed Form 144 to sell 36,759 shares of Moderna, with an estimated value

May 8, 2026

NEUTRAL COURT-RULING 3/10

Analysis based on filing metadata only — document content was unavailable

Mar 30, 2026

NEUTRAL DEFA14A 3/10

Analysis based on filing metadata only — document content was unavailable

Mar 16, 2026

BEARISH 8-K 8/10

Moderna entered into a settlement agreement with Arbutus Biopharma and Genevant Sciences to resolve

Mar 5, 2026

BULLISH INST-CLUSTER 7/10

Three major institutions — Fidelity, Norges Bank, and RenTech — significantly increased or initiated

Feb 28, 2026

∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Strong Sell (13% buy). Based on 30 analysts: 0 strong buy, 4 buy, 19 hold, 4 sell, 3 strong sell.

Analyst Price Targets

$43.30 mean target -9.3% upside Sell (3.04)

$21.00 Low $69.00 High

Metric	Value
Current Price	$47.73
Target Low	$21.00
Target Mean	$43.30
Target Median	$45.00
Target High	$69.00
# Analysts	20
Recommendation	Sell (3.04)

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q 2026-06-30	$-2.09	$-2.52	$-1.80	2.0%	+0.1%	6↑ 4↓	$0.1B	-27.1%	15
Next Q 2026-09-30	$-1.13	$-1.78	$-0.33	-121.4%	+1.5%	2↑ 8↓	$0.9B	-10.3%	15
Current FY 2026-12-31	$-8.65	$-9.48	$-7.52	-19.1%	+0.1%	4↑ 13↓	$2.1B	7.7%	21
Next FY 2027-12-31	$-4.72	$-6.68	$-0.08	45.3%	+0.1%	10↑ 5↓	$2.5B	20.0%	20

Current Quarter EPS Revision History

Timepoint	EPS Estimate	Change
Current	$-2.086
7d ago	$-2.086
30d ago	$-2.089	+0.002
60d ago	$-2.128	+0.042
90d ago	$-2.096	+0.010

9 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.

Individual Analyst Actions

Date	Analyst Firm	Action	Previous Rating	New Rating
Jun 8, 2026	B of A Securities	MAINTAIN	Underperform	Underperform
May 4, 2026	UBS	MAINTAIN	Neutral	Neutral
May 4, 2026	Goldman Sachs	MAINTAIN	Neutral	Neutral
May 4, 2026	Evercore ISI Group	MAINTAIN	In-Line	In-Line
May 4, 2026	RBC Capital	MAINTAIN	Sector Perform	Sector Perform
Apr 2, 2026	Barclays	MAINTAIN	Equal-Weight	Equal-Weight
Feb 23, 2026	Piper Sandler	MAINTAIN	Overweight	Overweight
Feb 17, 2026	Goldman Sachs	MAINTAIN	Neutral	Neutral
Feb 17, 2026	RBC Capital	MAINTAIN	Sector Perform	Sector Perform
Feb 17, 2026	Evercore ISI Group	MAINTAIN	In-Line	In-Line
Dec 12, 2025	Morgan Stanley	MAINTAIN	Equal-Weight	Equal-Weight
Dec 12, 2025	Jefferies	INITIATE	—	Hold

Monthly Consensus History

Period	Strong Buy	Buy	Hold	Sell	Strong Sell	Buy %
Jun 1, 2026	0	4	19	4	3	13%
May 1, 2026	2	7	18	2	1	30%
Apr 1, 2026	0	3	21	3	3	10%
Mar 1, 2026	0	3	21	3	3	10%
Feb 1, 2026	0	3	21	3	3	10%
Jan 1, 2026	0	4	19	4	3	13%
Dec 1, 2025	0	4	18	4	3	14%
Nov 1, 2025	0	4	18	5	3	13%

Strong BuyBuyHoldSellStrong Sell

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

54°

Neutral

Bearish Neutral Bullish

8 mentions 4 bullish 3 bearish 8 time periods

Reddit Sentiment History

Date	Mentions	Sentiment	Bullish	Bearish	Threads
May 29, 2026	1	40° Cool	0	1	1
May 14, 2026	1	60° Warm	1	0	1
May 14, 2026	1	60° Warm	1	0	1
May 8, 2026	1	60° Warm	1	0	1
May 8, 2026	1	60° Warm	1	0	1
Mar 12, 2026	1	56° Neutral	0	0	1
Feb 25, 2026	1	40° Cool	0	1	1
Feb 11, 2026	1	40° Cool	0	1	1

Recent Reddit Threads

r/options Bearish 11d 16h ago

MRNA bearish flow read, but IV is too expensive for naked puts

▲ 1 💬 0 ⚡ 0.5

r/stocks Bullish 26d 9h ago

What could be Moderna's "ozempic moment"? (Why MRNA is a great bet right now)

▲ 1 💬 0 ⚡ 0.5

r/options Bullish 1mo ago

Unusual Options Activity In MRNA

▲ 1 💬 0 ⚡ 0.5

r/options Neutral 2mo ago

MRNA

▲ 1 💬 0 ⚡ 0.5

r/wallstreetbets Bearish 3mo ago

First month option trading

▲ 1 💬 2 ⚡ 0.0

r/options Bearish 3mo ago

MRNA odd option activity observed prior to the crash.

▲ 13 💬 13 ⚡ 0.1

Aug 5, 2026

fda_pdufa

PDUFA: MRNA — mRNA-1010 in Seasonal flu — 2026-08-05

FDA target action date 2026-08-05 for MRNA (Moderna, Inc.). Drug: mRNA-1010. Indication: Seasonal flu. U.S. FDA has assigned a PDUFA goal date for mRN

Jul 30, 2026

earnings_calendar

MRNA Q2 2026 Earnings Before Market Open — 2026-07-30

EPS est: $-2.14 | Rev est: $0.1B

Jun 9, 2026

short_volume

Short Volume: MRNA — 65.9% short (1.2M / 1.8M)

Short: 1,194,360 | Exempt: 12,719 | TRF Vol: 1,812,415 | Short Ratio: 65.9% | Off-exchange volume (dark pool + OTC)

Jun 8, 2026

short_volume

Short Volume: MRNA — 61.2% short (0.9M / 1.5M)

Short: 888,278 | Exempt: 105,549 | TRF Vol: 1,450,269 | Short Ratio: 61.2% | Off-exchange volume (dark pool + OTC)

Jun 5, 2026

short_volume

Short Volume: MRNA — 60.4% short (1.4M / 2.3M)

Short: 1,417,456 | Exempt: 21,535 | TRF Vol: 2,347,312 | Short Ratio: 60.4% | Off-exchange volume (dark pool + OTC)

Jun 4, 2026

Clinical Trial

A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

Phase Phase 2 — COMPLETED

Jun 4, 2026

clinical_trial_readout

Results Pending: mRNA-1647 (Phase 2) — Completed 23d ago

Trial: A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age Sponsor: Moder

Jun 4, 2026

Clinical Trial

A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age

Phase Phase 3 — COMPLETED

Jun 4, 2026

clinical_trial_readout

Results Pending: mRNA-1345 (Phase 3) — Completed 69d ago

Trial: A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60

Jun 4, 2026

short_volume

Short Volume: MRNA — 60.8% short (1.6M / 2.6M)

Short: 1,603,038 | Exempt: 291 | TRF Vol: 2,635,921 | Short Ratio: 60.8% | Off-exchange volume (dark pool + OTC)

Jun 3, 2026

short_volume

Short Volume: MRNA — 60.1% short (1.6M / 2.7M)

Short: 1,600,180 | Exempt: 3,096 | TRF Vol: 2,662,578 | Short Ratio: 60.1% | Off-exchange volume (dark pool + OTC)

Jun 1, 2026

short_volume

Short Volume: MRNA — 56.7% short (1.5M / 2.6M)

Short: 1,461,828 | Exempt: 2,378 | TRF Vol: 2,579,212 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)

May 29, 2026

short_volume

Short Volume: MRNA — 61.5% short (1.2M / 2.0M)

Short: 1,239,654 | Exempt: 2,077 | TRF Vol: 2,016,332 | Short Ratio: 61.5% | Off-exchange volume (dark pool + OTC)

May 28, 2026

short_volume

Short Volume: MRNA — 57.3% short (1.1M / 2.0M)

Short: 1,130,005 | Exempt: 0 | TRF Vol: 1,973,794 | Short Ratio: 57.3% | Off-exchange volume (dark pool + OTC)

May 27, 2026

short_volume

Short Volume: MRNA — 56.5% short (0.8M / 1.4M)

Short: 773,054 | Exempt: 104 | TRF Vol: 1,368,256 | Short Ratio: 56.5% | Off-exchange volume (dark pool + OTC)

May 26, 2026

short_volume

Short Volume: MRNA — 55.6% short (0.8M / 1.4M)

Short: 779,550 | Exempt: 122 | TRF Vol: 1,401,458 | Short Ratio: 55.6% | Off-exchange volume (dark pool + OTC)

May 22, 2026

short_volume

Short Volume: MRNA — 63.5% short (0.8M / 1.2M)

Short: 790,912 | Exempt: 1,795 | TRF Vol: 1,245,121 | Short Ratio: 63.5% | Off-exchange volume (dark pool + OTC)

May 18, 2026

Clinical Trial

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

Phase Phase 2 — ACTIVE_NOT_RECRUITING

May 8, 2026

Clinical Trial

A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes

Phase Phase 2 — COMPLETED

May 6, 2026

Clinical Trial

A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia

Phase Phase 2 — TERMINATED

Mar 30, 2026

Enforcement

1:24-cv-01151 Northwestern University v. Moderna, Inc. et al

Court ruling from United States District Court for the District of Delaware. Docket: N/A